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Summary
 
The infusion of TIL586 along with interleukin-2 into the autologous patient with metastatic
melanoma resulted in the objective regression of tumor. A gene encoding a tumor antigen rec-
ognized by TIL586 was previously isolated and shown to encode gp75 or TRP-1. Here we re-
port that TRP-2 was identified as a second tumor antigen recognized by a HLA-A31–
restricted CTL clone derived from the TIL586 cell line. The peptide LLPGGRPYR epitope
was subsequently identified from the coding region of TRP-2 based on studies of the recogni-
tion of truncated TRP-2 cDNAs and the HLA-A31 binding motif. This epitope peptide was
capable of sensitizing target cells for lysis by a CTL clone at 1 nM peptide concentration. Al-
though some modified peptides could be recognized by the CTL clone, none were found to be
better recognized by T cells than the parental peptide. Like other melamona differentiation an-
tigens, TRP-2 was only expressed in melanoma, melanocytes, and retina, but not in other hu-
man tissues tested.
 
T
 
he adoptive transfer of tumor infiltrating lymphocytes
(TIL)
 
1
 
 plus IL-2 into the autologous patient with meta-
static melanoma can result in the objective regression of tu-
mor (1, 2), suggesting that T cells play an important role in
tumor rejection in vivo. To understand the molecular basis
of T cell–mediated antitumor responses, effort has been di-
rected toward the identification of tumor antigens recog-
nized by T cells and has led to the identification of a num-
ber of genes encoding tumor antigens in human melanoma
(3–8). These antigens can be divided into several classes
based on their expression pattern. One class of tumor anti-
gens such as MAGE1, MAGE3, BAGE, and GAGE are en-
coded by genes that are expressed only in tumor, testis, and
placenta, but not other normal human tissues (9–12). The
second class of antigens such as MART-1/Melan-A (13, 14),
gp100 (15), tyrosinase (16, 17), and gp75/TRP-1 (18) are
differentiation antigens encoded by genes that are expressed
only in melanocytes, melanomas, and normal retinal tissue.
These latter antigens are nonmutated self proteins. How-
ever, several mutated antigens were also identified to be
recognized by T cells, including CDK4 (19), 
 
b
 
-catenin
(20), and MUM-1 (21).
Recently, we cloned the 
 
gp75/TRP-1
 
 gene encoding
a tumor antigen recognized by the HLA-A31–restricted
TIL586 (18), which was previously shown to have in vivo
antitumor activity when infused along with IL-2 into the
autologous patient with melanoma. Surprisingly, the pep-
tide recognized by TIL586 was found to be derived from
the gene product translated from an alternative open read-
ing frame of the 
 
TRP-1
 
 gene (22). Site-directed mutagene-
sis experiments indicated that the ATG start codon in the
alternative open reading frame was essential for generating
the epitope recognized by TIL586. 6 of 15 T cell clones es-
tablished from the TIL586 cell line were capable of recog-
nizing 586mel tumor cells as well as 586EBV B cells pulsed
with the peptide ORF3P derived from the alternative open
reading frame of the 
 
TRP-1
 
 gene (22). However, some T cell
clones isolated from the same TIL586 line did not recog-
nize TRP-1– and HLA-A31–transfected COS-7 cells and its
ORF3P (MSLQRQFLR) peptide-pulsed 586EBV B cells,
although they were capable of recognizing 586mel and HLA-
A31
 
1
 
 melanocytes.
In this report, we describe the identification of TRP-2 as
a new tumor antigen recognized by CTL clones derived
from tumor reactive TIL line. 
 
TRP-2
 
 is a member of the
tyrosinase-related gene family. Further experiments have
allowed us to identify the epitope peptide from the TRP-2
coding sequence recognized by T cell clones, suggesting
that T cells recognized a nonmutated self peptide.
 
Materials and Methods
 
Chemicals and Reagents.
 
The following chemicals and reagents
were purchased from the sources indicated: RPMI 1640, AIM-V
media, Lipofectamine, G418 (GIBCO BRL, Gaithersburg, MD);
 
1
 
Abbreviations used in this paper:
 
 E/T, effector/target ratio; TIL, tumor in-
filtrating lymphocyte.
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the eukaryotic expression vector pCR3 (Invitrogen, San Diego,
CA); anti–HLA-A31 monoclonal antibody (One lambda; Canoga
Park, CA); anti–immunoglobulin M antibody conjugated with flu-
orescein isothiocyanate (Vector Labs., Inc., Burlingame, CA).
 
T Cell Clones and Lines.
 
TIL586 were isolated from the tu-
mor specimen of a patient with metastatic melanoma and grown
in medium containing IL-2 (6,000 IU/ml) (Chiron Corp., Em-
eryville, CA) for 32–60 d as previously described (23). TIL586 were
predominantly CD8
 
1
 
 T cells. The T cell clones were generated
by limiting dilution methods (at 1 cell/well) from the TIL586 cell
line, and used allogeneic PBL (1 
 
3
 
 10
 
3
 
 cells/well) as feeder cells
in RPMI1640 containing 10% human AB sera and 500 IU IL-2.
After 12 d, T cell clones were then expanded in AIM-V medium
containing 6,000 IU/ml IL-2. To obtain a optimal expansion, we
used the OKT3 expansion method described by Walter et al. (24).
Briefly, on day 0, 5 
 
3
 
 10
 
4
 
–5 
 
3
 
 10
 
5
 
 T cells were cocultured with
HLA-A31
 
1
 
 PBL (500:1, PBL/T cell) and 586EBV B cells (100:1,
EBV/T cell) in 25 ml RPMI 1640 containing 11% human sera,
30 ng/ ml OKT3 antibody, and antibiotics. On day 1, IL-2 was
added at final concentration of 180 IU/ml. The medium was
changed with fresh medium containing 11% human sera, and 180
IU/ml of IL-2 on day 5. The medium was then changed every 3 d.
On days 12–14, T cells were harvested, counted, and cryopreserved.
Melanoma cell lines 397mel, 397mel/A31, 586mel, 624mel,
624mel/A31, and EBV transformed B cell lines 586EBV and
1510EBV were established in our laboratory and cultured in RPMI
1640 medium containing 10% FCS. Normal cultured melano-
cytes derived from infant foreskin (NHEM680; Clonetics Corp.,
San Diego, CA) were cultured in melanocyte growth medium
(MGM; Clonetics). The COS-7 cell line was provided by Dr. W.
Leonard (National Institutes of Health).
 
GM-CSF Secretion Assay.
 
DNA transfection and GM-CSF
assays were performed as previously described (18). Briefly, 200
ng of DNA encoding antigens and 50 ng of the HLA-A31 DNA
were mixed with 2 
 
m
 
l of lipofectamine in 100 
 
m
 
l of DMEM for
15–45 min. The DNA/lipofectamine mixture was then added to
the COS-7 (5 
 
3
 
 10
 
4
 
) cells and incubated overnight. The follow-
ing day, cells were washed twice with DMEM medium. TIL586
was added at a concentration of 1 
 
3
 
 10
 
5
 
 cells/well in AIM-V me-
dium containing 120 IU/ml of IL-2. For T cell clones, only 1–2 
 
3
 
10
 
4
 
 cells/well were added. After 18–24 h incubation, 100 
 
m
 
l of
supernatant was collected and GM-CSF was measured in a stan-
dard ELISA assay (R & D Sys., Inc., Minneapolis, MN). For test-
ing peptide recognition, 586EBV or T2 cells were incubated with
peptides at 37
 
8
 
C for 90 min, and then washed three times with
AIM-V medium containing 120 IU/ml of IL-2. T cells were
added and incubated for an additional 18–24 h; 100 
 
m
 
l of super-
natant was collected for GM-CSF assay.
 
ExoIII/S1 Deletion Constructions and Subcloning.
 
TRP-2 cDNA
was a gift of Dr. Shibahara (25), and subcloned into the pCR3
vector with a CMV promoter for expression. To make a series of
deletions, the plasmid pCR3 containing TRP-2 cDNA was di-
gested with XbaI and filled in with 
 
a
 
-phosphorothioate deoxyri-
bonucleotide triphosphates to block ExoIII nuclease digestion.
The linearized DNA was subjected to the second restriction en-
zyme digestion to generate one end sensitive to ExoIII. ExoIII
nuclease/Mung bean nuclease deletion was performed according
to the manufacturer’s instructions (Stratagene Corp., La Jolla,
CA). All deletion constructs were sequenced to determine the lo-
cation of DNA sequence being removed. pTA plasmid was a de-
rivative of pCR3-TRP2, in which an ApaI DNA fragment was
deleted from the 3
 
9
 
 end of 
 
TRP-2
 
 gene. pTK was created after
removal of a KpnI DNA fragment from the 3
 
9
 
 end of the 
 
TRP-2
 
gene. pTP was generated by deleting an internal PstI fragment
and religation.
 
Northern Blot Analysis.
 
Total RNA was isolated by the guani-
dine isothiocyanate/cesium chloride centrifugation method. To-
tal RNA from human normal tissue was purchased from Clon-
tech (Palo Alto, CA). 20 
 
m
 
g of total RNA was subjected to
electrophoresis in a 1.2% agarose formaldehyde gel and trans-
ferred to a nylon membrane. A 2.0-kb DNA fragment of the
 
TRP-2
 
 gene was labeled with 
 
32
 
P-
 
a
 
-CTP by the random priming
method. Prehybridization and hybridization were performed ac-
cording to the QuickHyb protocol (Stratagene Corp.). Mem-
branes were washed twice with 2
 
3
 
 SSC/0.1% SDS at room tem-
perature for 15 min and twice with 0.1
 
3
 
 SSC/0.1% SDS at 60
 
8
 
C
for 30 min. The autoradiography was performed at 
 
2
 
70
 
8
 
C.
 
Cytotoxicity Assays.
 
Cytolysis was determined by use of cal-
cein AM ( Molecular Probes Inc., Eugene, OR). Briefly, T2 or
586EBV B cells were pulsed with peptides in RPMI1640/
5%FCS for 90 min. Tumor cells and the peptide pulsed EBV B
cells were labeled with calcein AM (15 
 
m
 
l of 1 mg/ml calcein
AM for every 1 
 
3
 
 10
 
6
 
 cells) for 30 min at 37
 
8
 
C. After incubation,
cells were washed three times with AIM V/120 IU IL-2. 1 
 
3
 
 10
 
3
 
target cells were mixed with T cells at various E/T (effector/tar-
get ratio). After 4 h incubation at 37
 
8
 
C, 5 
 
m
 
l of bovine hemoglo-
bin quench solution containing ethidium bromide was added.
The plate was read by lambda scan. The percentage of lysis was
calculated from the following equation: [1 
 
2
 
 (
 
A
 
 
 
2
 
 
 
B
 
)/(
 
C
 
 
 
2
 
 
 
B
 
)] 
 
3
 
100 where 
 
A
 
 is the reading of nonlysed cells in the presence of
T cells, 
 
B
 
 is background signal value, and 
 
C
 
 is the maximum sig-
nal value from target cells.
The peptides were synthesized by a solid-phase method using a
peptide synthesizer (AMS 422; Gilson Co., Inc., Worthington,
OH). Some peptides were purified by HPLC and became 
 
.
 
98%
in purity. The peptide mass of some peptides was confirmed by
mass spectrometry analysis.
 
Results
 
Recognition of New Antigens on Tumor Cells by CTL Clones.
 
In previous studies, we isolated a number of T cell clones
from the TIL586 cell line by the limiting dilution method
(22). Among them, six clones recognized 586EBV B cells
pulsed with the ORF3P peptide derived from a gene prod-
uct translated from an alternative open reading of the 
 
TRP-
1/gp75
 
 gene, and the autologous 586mel tumor cells, but
did not recognize 586EBV B cells pulsed with an irrelevant
peptide. TIL586-C1 was a representative of these T cell
clones as shown in Fig. 1. However, several T cell clones
isolated from the same TIL586 cell line recognized neither
586EBV B cells pulsed with the TRP-1 peptide ORF3P
nor COS cells transfected with TRP-1 and HLA-A31
cDNAs, but were capable of recognizing 586mel as well as
HLA-A31
 
1
 
 NHEM680 melanocyte line (Fig. 1). These re-
sults suggested that these T cell clones recognized addi-
tional tumor antigens on the 586mel tumor cells. These T
cell clones were then expanded to obtain enough cells for
screening cDNA libraries or testing other cDNAs for rec-
ognition by methods described in the Materials and Meth-
ods section. One of the clones, CTL clone 4, was success-
fully expanded and used for further studies as described
below. 
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Identification of a cDNA Encoding a Tumor Antigen Recog-
nized by T Cell Clones.
 
To determine the HLA molecule
responsible for presenting antigen to CTL clone 4, we
transfected HLA-A31 cDNA into HLA-A31–negative tu-
mor lines such as 397mel and 624mel and tested for recog-
nition by the CTL clone. Transfectants of 397mel and
624mel expressing HLA-A31 were significantly recognized
by CTL clone 4 (Table 1). Furthermore, these T cells were
also capable of recognizing the HLA-A31–positive alloge-
neic tumor line 1353mel, indicating that recognition of the
tumor antigen by CTL clone 4 was HLA-A31 restricted.
Since only a limited number of T cells were available,
we first tested whether or not these T cells recognized pre-
viously identified tumor antigens or melanocyte-lineage
differentiation proteins. Recognition of COS-7 cells trans-
fected with HLA-A31 cDNA and genes encoding the known
tumor antigens or putative antigens including MART-1 (13),
gp75 (18), gp100 (15), tyrosinase (17), p15 (26), and TRP-2
(25, 27) by CTL clone 4 was tested. COS cells transfected
with HLA-A31 alone or TRP-2 alone did not confer rec-
ognition by the T cell clones. However, COS cells trans-
fected with HLA-A31 and TRP-2 cDNA stimulated GM-
CSF release from T cells, whereas COS cells transfected
with HLA-A31 and other genes did not, indicating that the
T cell clone 4 recognized TRP-2 as a tumor antigen in an
HLA-A31 restricted manner (Table 1 and Fig. 2). TRP-2
is located on the human chromosome 13 and has been
shown to be a member of the tyrosinase-related gene fam-
ily and shares a 40–45% amino acid sequence identity with
tyrosinase and gp75/TRP-1 (25, 27). TRP-2 encodes a
protein with 519 amino acids and has been demonstrated to
have DOPAchrome tautomerase activity involved in mela-
nin synthesis (27).
 
Expression of the TRP-2 Gene.
 
Northern blot analyses were
performed using TRP-2 cDNA as a probe to evaluate the
expression pattern of TRP-2 in different tissues. Normal
retinal tissue was shown to be the only positive expression
of TRP-2 among the normal human tissues tested. The ex-
pression pattern of TRP-2 in melanoma cell lines and other
cell lines is listed in Table 2. 22 of 27 melanoma cell lines
were found to express TRP-2. The Burkitt’s B cell line
Daudi and the breast cancer cell line MDA231 were nega-
tive, in agreement with previous results (27). Thus, like ty-
rosinase, TRP-1, gp100, and MART-1, the expression
pattern of this gene appeared to be restricted to melanomas,
normal melanocyte cell lines, and retina.
 
The Peptide Epitopes Recognized by T Cells.
 
To determine
the antigenic epitopes from TRP-2, a series of nested dele-
tions of the 
 
TRP-2
 
 gene from the 3
 
9
 
 end using ExoIII/S1 nu-
clease, as well as DNA fragments encoding the truncated
form of TRP-2, were generated. These deletions and sub-
Figure 1. Recognition of var-
ious target cells and the antigenic
peptide by CTL clones derived
from TIL586. T cell clones were
generated by limiting dilution (1
cell/well) from the TIL586 cell
line and were further expanded
in AIM-V medium containing
6,000 IU/ml IL-2. GM-CSF se-
cretion by CTL clone 586TIL-
C1 (left) and clone 4 (right)
was measured after coculturing
with a normal melanocyte cell
line NHEM680 (HLA-A311),
586EBV B cells pulsed with the
ORF3P peptide or irrelevant
peptide, 397mel or 586mel cells.
 
Table 1.
 
Specific Secretion of GM-CSF by CTL Clone 4 is 
HLA-A31–Restricted
 
Stimulators
GM-CSF
secretion Cell lines
Transfected
gene
HLA-31
expression
 
pg/ml
 
None None
 
2,
 
10
397mel
(TRP1
 
2
 
/TRP2
 
1
 
) None
 
2
 
23
397mel
(TRP1
 
2
 
/TRP2
 
1
 
) HLA-A31
 
1
 
2,840
624mel
(TRP1
 
1
 
/TRP2
 
1
 
) None
 
2
 
39
624mel
(TRP1
 
1
 
/TRP2
 
1
 
) HLA-A31
 
1
 
670
1353mel
(TRP1
 
1
 
/TRP2
 
1
 
) None
 
1
 
879
586mel
(TRP1
 
1
 
/TRP2
 
1
 
) None
 
1.
 
4,000
586EBVB None
 
1
 
29
COS-7 None
 
2
 
35
COS-7 HLA-A31
 
1
 
30
GM-CSF in the supernatant was measured after 24 h incubation of
2 
 
3
 
 10
 
4
 
 CTL clone 4 cells with either melanoma cell lines or COS-7
transfected with the HLA-A31 cDNA. 
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cloned constructs were transfected into COS-7 cells along
with the pBK-CMV plasmid containing the HLA-A31
cDNA. Recognition of the transfected COS cells was
tested with the CTL clone 4 by measuring GM-CSF cy-
tokine release from the CTL clone. Fig. 3 indicates that
pTD1, 2, and 3 constructs retained the ability to stimulate
cytokine release from the CTL clone 4, but pTD4 and
pTD5 lost the stimulating activity to the CTL clone 4, in-
dicating that the epitope(s) recognized by the CTL clone 4
was located in the region of nucleotides 836–1045. This
was consistent with results obtained by the subcloning ex-
periments. Although pTA and pTP lost the ability to stim-
ulate cytokine release from CTL clone 4, pTK still re-
mained positive in the cytokine release assay. Therefore,
the epitopes resided in a DNA fragment flanked by the first
PstI and KpnI sites as shown in Fig. 4.
To identify the epitopes from the coding region of this
small DNA fragment, we made five synthetic peptides
based on the peptide binding motif for HLA-A31 (hydro-
phobic residues at position 2 and positively charged resi-
dues at position 9) (28). These peptides were pulsed onto
586EBV B cells and tested for their ability to stimulate cy-
tokine release by CTL clone 4. As shown in Table 3, pep-
tide TRP
 
197–205
 
 was strongly recognized by CTL clone 4
when pulsed on 586EBV B cells. The recognition of this
peptide by CTL clone 4 was observed only when the pep-
tide was pulsed onto HLA-A31
 
1
 
 EBV B cells such as
586EBV and 1510EBV, but not onto HLA-A31–negative
T2 cells. CTL clone 4 did not recognize the ORF3P pep-
tide derived from the alternative open reading frame of the
 
TRP-1
 
 gene. These results demonstrated that TIL586-C1
specifically recognized the ORF3P peptide derived from
TRP-1 and CTL clone 4 specifically recognized the pep-
tide derived from TRP2. No cross reactivity was observed,
Figure 2. Identification of TRP-2 as a tumor antigen recognized by
CTL clone 4. GM-CSF release by CTL clone 4 was measured after co-
culture with COS-7 cotransfected with the HLA-A31 cDNA along with
genes encoding MART-1, gp75/TRP-1, gp100, tyrosinase, p15, and
TRP-2. Control stimulator cells included 586mel, 397mel, COS-7 alone,
and COS-7 transfected with the HLA-A31 cDNA.
 
Table 2.
 
Expression of TRP-2 in Different Cell Lines and 
Human Tissues Tested
 
Cell lines Expression of TRP-2
397mel
 
1
526mel 1
501mel 1
537mel 2
553Bmel 1
586mel 1
624mel 1
677mel 1
679mel 2
697mel 1
729mel 2
894mel 1
836mel 2
888mel 1
928mel 1
1290mel 1
1300mel 1
952mel 1
HT144 1
1011mel 1
1088mel 1
SK23 1
SK28 1
Maisel 1
Groves 1
WN266 1
A375 2
586EBVB 2
Melanocytes
FM906 1
FM680 1
Other tumor lines
Daudi 2
MDA231 2
Normal tissues
Retina 1
Testis 2
Brain 2
Spleen 2
Liver 2
Fetal liver 2
Thymus 2
Lung 2
Expression of TRP-2 was tested by Northern blot analysis with 10–20
mg of total RNA and probed with the TRP-2 cDNA fragment. Daudi
is a Burkitt’s B cell line and MDA231 is a breast cancer cell line.2211 Wang et al.
although both ORF3P and TRP1972205 were presented to
T cells by HLA-A31 molecules.
Characterization of TRP197–205 Peptide. Titration experi-
ments demonstrated that 1 nM of peptide was sufficient to
stimulate GM-CSF release from the T cell clone 4 and the
stimulation reached a plateau at 500 nM (Fig. 4 A). Lysis of
586EBV B cells pulsed with TRP1972205 by CTL clone 4
was also determined at various peptide concentrations (Fig.
4 B). Similar to cytokine release assays, lysis of target cells
by the CTL clone 4 was detected at 1 nM peptide concen-
tration. Maximum lysis was seen at 100 nM of peptide con-
centration. CTL clone 4 was capable of lysing 586EBV
pulsed with TRP197-205 and 586mel tumor cells even at
low E/T, but failed to lyse 586EBV B cells alone, or 586
EBV B cells pulsed with the control peptide ORF3P, or
the HLA-A31 negative 397mel line (Fig. 4).
The majority of human melanoma antigens identified to
date are nonmutated self-antigens, and the T cell recogni-
tion and binding affinity of these self-peptides to the corre-
sponding MHC molecules have in some instances been im-
proved by substitution of amino acids at anchor residues
(29). A number of synthetic peptides including 8- or 10-mer,
and modified peptides as indicated in Table 4 were made and
tested for recognition by CTL clone 4 when pulsed onto
586EBV B cells. The 10-mer TLLGPGRPYR, in which
one amino acid was extended at the NH2 terminus of
TRP1972205, was still recognized by CTL clone 4 when
pulsed on 586EBV B cells, but the reactivity was z60% of
the overlapping 9-mer LLGPGRPYR. In contrast, peptides
LLGPGRPYRA or LGPGRPYR had little or no reactiv-
ity compared with the overlapping 9-mer LLGPGRPYR.
These results showed that the 9-mer LLGPGRPYR was
better recognized than its derivatives, the 8- or 10-mers.
Based on the binding motif of HLA-A31, we generated a
few modified peptides with substitution of amino acids at
anchor residues positions 2 and 9 as well as at other posi-
tions. Although the Arg residue at position 9 in the
COOH terminus could be substituted with the Lys residue,
the modified peptide retained only 60% of the activity of
the parental peptide. No activity was detected by other
amino acid substitutions at this position (Table 4). Substitu-
tion of a Leu residue at position 2 with either Ser, Ile, or
Val residues retained the same activity or reduced the activ-
ity to 60% of the parental peptide while substitution with
Ala or Phe at this position dramatically reduced the ability
to stimulate cytokine release from T cells (Table 4). Other
modifications at positions 1, 3, and 6 of the peptide either
completely abrogated or dramatically reduced T cell recog-
nition.
Discussion
In the last few years, tyrosinase, MART-1, gp100, and
TRP-1/gp75 have been identified as human melanoma an-
tigens recognized by T cells derived from human PBLs or
TILs. Here, we provide evidence that TRP-2, another
melanoma/melanocyte differentiation antigen of the tyrosi-
Figure 3. Construction of deletions and subclones of the TRP-2 gene
and T cell recognition. The full-length cDNA of TRP-2 which com-
prises the 1,557-bp open reading frame is shown. Nucleotides are num-
bered from the first nucleotide from the 59 untranslated region of TRP-2
cDNA. A series of deletion constructs and subcloning of DNA fragments
were made. T cell recognition of each construct was determined after
coculturing CTL clone 4 with COS-7 cotransfected with the DNA frag-
ments shown above and the HLA-A31 gene.
Figure 4. Antigenic peptide and partial coding sequence of TRP-2.
The partial nucleotide and amino acid sequences of the TRP-2 gene are
shown. The length and 39 terminus of the DNA fragments in pTD4,
pTA, pTD3, and pTK are indicated by arrows and the restriction sites for
ApaI, PstI, and KpnI, are marked. The antigenic peptide sequence recog-
nized by CTL clone 4 is in bold and underlined.2212 CTL Recognition of TRP-2
nase protein family, is indeed a new tumor antigen recog-
nized by HLA-A31–restricted T cells. TIL586 cell line rec-
ognized both COS-7 cells transfected with HLA-A31 plus
TRP-2 cDNA, and HLA-A31–positive EBV B cells pulsed
with the TRP1972205 peptide derived from TRP-2. How-
ever, recognition of TRP-2 by TIL586 cell line was much
lower than that of TRP-1 or the ORF3P peptide (data not
shown). This is probably due to a difference in the percent-
Table 3. Identification of Synthetic Peptides with Reactivity to T Cell Clones
Target cells pulsed with peptide
GM-CSF release
TIL586-C1 (TRP-1) CTL clone 4 (TRP-2)
pg/ml
586EBV 1 TRP186–194 VWLHYYSVR (TRP-2) ,50 ,50
586EBV 1 TRP185–194 FVWLHYYSVR (TRP-2) ,50 ,50
586EBV 1 TRP194–202 RDTLLGPGR (TRP-2) ,50 ,50
586EBV 1 TRP197–205 LLGPGRPYR (TRP-2) ,50 .4,000
586EBV 1 TRP213–221 GPAFVTWHR (TRP-2) ,50 ,50
586EBV 1 ORF3P MSLQRQFLR (TRP-1) .8,000 ,50
1510EBV 1 TRP197–205 LLGPGRPYR (TRP-2) ,50 .4,000
1510EBV 1 ORF3P MSLQRQFLR (TRP-1) .6,000 ,50
T2 1 TRP197–205  LLGPGRPYR (TRP-2) ,50 ,50
T2 1 ORF3P MSLQRQFLR (TRP-1) ,50 ,50
586EBV 1 none ,50 ,50
586mel 1 none .5,000 .3,000
586EBV cells were incubated with individual peptides at a concentration of 1 mg/ml for 90 min. GM-CSF release was measured after coincubation
of peptide-loaded 586EBV cells with T cell clones recognizing either TRP-1 or -2. GM-CSF secretion by T cells alone without stimulators was sub-
tracted. 586EBV and 1510EBV were EBV transformed B cell lines expressing HLA-A31.
Figure 5. Characterization of the antigenic peptide recognized by CTL clone 4. (A) GM-CSF release by T cells at different peptide concentrations.
586EBV (A311) were pulsed with the TRP197–205 peptide ( ) and T2 (non-A31) cells were pulsed with the TRP197–205 ( ) at various peptide con-
centrations for 90 min. ORF3P as a control peptide was pulsed onto 586EBV B cells (--n--). GM-CSF release by CTL clone 4 was determined after co-
incubation with 586EBV B cells pulsed with TRP197–205 and ORF3P, and T2 cells pulsed with TRP197–205. (B) Sensitization of the target cells for lysis by
CTL clone 4 at different peptide concentrations. 586EBV B cells were incubated with TRP197–205 ( ), an irrelevant peptide ORF3P (--n--), and T2
cells pulsed with TRP197–205 ( ) at various peptide concentrations. After peptide incubation, target cells were labeled for 30 min. Following washes, cy-
tolytic activity of CTL clone 4 at an E/T of 40:1 was measured after a 4 h incubation of T cells with target cells. (C) Lysis of the target cells by CTL clone
4 at different E/T. Target 586EBV cells were separately incubated with TRP197–205 ( ) or the irrelevant peptides ORF3P (--n--), and target T2 cells
were incubated with the TRP197–205 peptide ( ) for 90 min. 586mel ( ) and 397mel ( ) were used as positive and negative controls, respectively. 2213 Wang et al.
age of subsets of the T cell population. Isolation of these T
cell clones from TIL586 allowed us to demonstrate that the
TRP-2 gene product is the second tumor antigen recog-
nized by this CTL. Of interest, two additional CTL clones
isolated from TIL586 were found to recognize tumor
586mel, but failed to recognize TRP-1 and -2 in the context
of HLA-A31 (Wang and Rosenberg, unpublished data), indi-
cating that CTLs derived from melanoma patient 586 rec-
ognized additional tumor antigens. T cell recognition of
multiple tumor antigens in a single tumor has been previ-
ously observed. TIL lines derived from many HLA-A2 pa-
tients recognized both MART-1 and gp100 (30, 31). Sev-
eral TIL lines obtained from patient 888 at different stages
of disease recognized tyrosinase (17), p15 (26), and b-cate-
nin (20); several CTL clones derived from the patient MZ2
recognized MAGE (9), BAGE (12), and GAGE (11), re-
spectively. Recognition of multiple tumor antigens by TIL
may explain the effective in vivo antitumor activity of these
T cells when infused into the autologous patients. It has
been demonstrated that tumor reactive CTL can be readily
generated from PBL of healthy individuals as well as mela-
noma patients by stimulation with peptides (32–34). The
effectiveness of the adoptive transfer of peptide-specific
CTL depends on the expression of the targeted tumor anti-
gens on tumor cells. Antigen-loss variants may overgrow, as
suggested by the observation that antigen-loss variants oc-
curred in vivo (35). Therefore, use of multiple antigen- or
multiple epitope-specific CTLs (consisting of subsets of T
cell populations) may be more effective in the treatment of
cancer patients and have advantages over CTL that recog-
nize a single antigen or epitope.
TRP-2 belongs to a class of shared, differentiation anti-
gens including tyrosinase, MART-1/Melan-A, gp100, and
TRP-1 or gp75. TRP-2 is one of the most highly ex-
pressed glycoproteins in human pigmented melanocytic cells
and melanoma. While its biological function is not com-
pletely known, TRP-2 has been shown to have DOPA-
chrome tautomerase activity which is involved in melanin
production (27). Mutation of this gene in black-haired
mice may be responsible for hair color change (36). A di-
rect correlation was observed between melanin content and
the expression of the four melanogenic proteins: tyrosinase,
gp100, TRP-1/gp75, and TRP-2 (37, 38). The TRP-2 pro-
tein contains two putative copper-binding sites, cysteine-
rich regions, and a transmembrane domain. Human TRP-2
has been mapped to chromosome 13 while the mouse
counterpart has been mapped to chromosome 14 in the re-
gion of the coat color mutation slaty. There is about a 40%
amino acid sequence identity between TRP-2 and tyrosi-
nase or TRP-1/gp75, but no CTL line or clone has been
found that recognizes a common peptide epitope among
the tyrosinase protein family.
The 9-mer TRP1972205 peptide recognized by CTL clone
4 is located at one of the copper binding sites in the coding
region of TRP-2. This peptide most efficiently stimulated
cytokine release from T cells compared with other peptides
including modified peptides tested in this study. This was
in agreement with the predicted HLA-A31–binding motif,
which indicates that Leu at position 2 and Arg at position 9
are the favorable residues. Although Leu at position 2 and
Arg at position 9 could be replaced with Ile and Ser at po-
sition 2 and Lys at position 9, respectively, with little or
minor loss of T cell recognition, substitutions of amino ac-
ids at positions 1, 3, or 6 led to dramatic or complete loss of
reactivity. It remained to be tested whether this is due to
the change of binding affinity of the modified peptides to
HLA-A31, or to abrogation of T cell receptor interacting
with the peptide/MHC complex.
Analysis of the structural similarities in HLA-A3, A11,
A31, A33, and A68 and their peptide binding motif has
suggested the existence of the A3-like supermotif (39). A
single epitope peptide could cross-react with HLA-A3,
A11, A31, A33, and A68 molecules which are cumula-
tively expressed in z40–50% of the general population. It
has been reported that the same peptide epitope derived
Table 4. Comparison of T Cell Reactivity of Modified Peptides
Target cells pulsed with peptides
CTL clone 4
GM-CSF release
pg/ml
586EBV 1 LLGPGRPYR 3,450
586EBV 1 TLLGPGRPYR 2,100
586EBV 1 LLGPGRPYRA 545
586EBV 1 LGPGRPYR ,50
586EBV 1 LIGPGRPYR 2,545
586EBV 1 LVGPGRPYR 2,100
586EBV 1 LSGPGRPYR 3,300
586EBV 1 LAGPGRPYR 550
586EBV 1 LFGPGRPYR ,50
586EBV 1 LLGPGRPYK 2,000
586EBV 1 LLGPGRPYH ,50
586EBV 1 ALGPGRPYR ,50
586EBV 1 RLGPGRPYR ,50
586EBV 1 KLGPGRPYR 420
586EBV 1 LLLPGRPYR ,50
586EBV 1 LLFPGRPYR ,50
586EBV 1 LLAPGRPYR ,50
586EBV 1 LLGPGFPYR 738
586EBV 1 LLGPGAPYR ,50
586EBV 1 LLGPGIPYR ,50
586EBV 1 LLGPGVPYR ,50
586EBV 1 LLGPGKPYR 321
586EBV ,50
586mel .3,000
586EBV cells were incubated with individual peptides at a concentra-
tion of 0.5 mg/ml for 90 min. GM-CSF release was measured after co-
incubation of peptide-loaded 586EBV cells with the CTL clone 4 cells.
GM-CSF secretion by T cells alone without stimulators was subtracted.
586EBV was a EBV transformed B cell line expressing HLA-A31.2214 CTL Recognition of TRP-2
from Hepatitis B virus nucleocapsid protein could be pre-
sented by HLA-A31 and -A68 molecules and recognized
by the corresponding HLA-A31– or -A68–restricted CTL
(40). We tested whether HLA-A31–restricted T cells rec-
ognized TRP-1 and TRP-2 epitopes when pulsed onto
HLA-A3–positive EBV B cells. Interestingly, weak recog-
nition was detected based on GM-CSF release from T cells
(data not shown). However, no recognition of HLA-A3–pos-
itive tumor cells was detected. We are now studying the bind-
ing of these HLA-A31–epitope peptides to HLA-A3 and A11
to determine whether CTL restricted by HLA-A3, -A11,
-A33, and -A68 could be generated from PBL using HLA-
A31–binding peptides.
Since TRP-2 is a nonmutated self antigen, this raises
questions about the nature and mechanism of immune re-
sponses to self antigens on growing tumor cells. Although
shared differentiation antigens like those encoded by tyrosi-
nase, MART-1/Melan-A, gp100, TRP-1, and -2 may serve
as useful targets for the immunotherapy of patients with
melanoma, anti-tumor activity might lead to self-tissue
destruction or autoimmune disease as well. Local depig-
mentation occurring in melanoma patients has been re-
ported to correlate with prolonged survival (41, 42) and
clinical response to chemoimmunotherapy (43). The de-
pigmentation resulting from the destruction of melanocytes
as a consequence of an immune response directed against
these differentiation antigens may be observed in patients
with melanoma responding to IL-2–based immunotherapy
(44). Patient 586 experienced partial regression (.50% re-
duction) of all measurable lesions after receiving the infu-
sion of TIL586 cells plus IL-2. However, no adverse effects
related to melanocyte destruction were observed. These
results suggest that CTLs directed against shared differentia-
tion antigens may mediate tumor destruction without
damage to normal tissues. Hara et al. have recently dem-
onstrated that passive immunization with a mouse monoclonal
antibody against TRP-1/gp75 TA99 induced protection
against and rejection of the TRP-11 B16F10 melanoma in
syngeneic mice (45). There was no evidence of decrease in
pigmentation, inflammation, or changes in cellular mor-
phology or tissue architecture in the eyes of mice treated
with antibody. Although coat color changes were observed
in regenerating hair on the trunk, the threshold dose re-
quired for coat color changes was fivefold greater than that
required for tumor regression (45).
The use of a mouse B16 melanoma model may be help-
ful in evaluating the potential autoimmune responses and
maximum antitumor activity induced by self-antigens. How-
ever, mouse melanoma antigens with properties similar to
the MART-1, gp100, tyrosinase, TRP-1, and -2 antigens
found in human melanoma have not been identified. Re-
cently, mouse TRP-2 has been identified as a tumor antigen
recognized by a CTL line against B16 melanoma (Bloom,
M.B., and J.C. Yang, personal communication). Like human
TRP-2, mouse TRP-2 was frequently expressed in the
samples of melanoma of Tyr-SV40E transgenic mice (46).
These results suggested that TRP-2 is a tumor antigen rec-
ognized by CTL in both mouse and human melanoma.
Mouse TRP-2 may represent an ideal tumor antigen to be
tested in mouse models and to evaluate questions important
for the development of effective immunotherapies in humans.
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